andrewkaretas, Author at Allogene

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Post author:andrewkaretas
Post published:December 16, 2024
Post category:Latest News

SOUTH SAN FRANCISCO, Calif. , Dec. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…

Continue Reading

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Post author:andrewkaretas
Post published:December 12, 2024
Post category:Latest News

SOUTH SAN FRANCISCO, Calif. , Dec. 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™…

Continue Reading

4: Statement of changes in beneficial ownership of securities

Post author:andrewkaretas
Post published:December 10, 2024
Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading

4: Statement of changes in beneficial ownership of securities

Post author:andrewkaretas
Post published:December 9, 2024
Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading

144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

Post author:andrewkaretas
Post published:December 9, 2024
Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading

Read more about the article Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

Post author:andrewkaretas
Post published:December 9, 2024
Post category:CD19 Scientific Publications

Continue Reading

144/A: Amendment to a previously filed 144

Post author:andrewkaretas
Post published:December 4, 2024
Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading

144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

Post author:andrewkaretas
Post published:December 2, 2024
Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading

December 2, 2024 11:00 AM EST : The Citizens JMP Hematology and Oncology Summit

Post author:andrewkaretas
Post published:November 27, 2024
Post category:Events

Continue Reading

December 3, 2024 8:00 AM EST : Piper Sandler 36th Annual Healthcare Conference

Post author:andrewkaretas
Post published:November 27, 2024
Post category:Events

Continue Reading

1
2
3
4
…
15
Go to the next page